Skip to main content
Home

Breadcrumb

  1. Home
  2. News
  3. Search results
Displaying results 101 - 125 of 673 Clear search
Zyme Communications
SLAS - Society for Laboratory Automation and Screening
Healthcare and Life Science 23 Mar 2026

SLAS announces the cohort for Innovation AveNEW at SLAS Europe 2026

Vienna, Austria, 23 March 2026: SLAS, the Society of Laboratory Automation and Screening, has introduced the 12 companies selected for the Innovation AveNEW program at SLAS Europe 2026 Conference and Exhibition, taking place 19-21 May in Vienna, Austria.

Zyme Communications
logo
Healthcare and Life Science 18 Mar 2026

ProImmune and the Roslin Institute collaborate to advance animal health science

Partnership will validate high quality, species specific Ankyron binders for key animal health science applications, including prevention and monitoring of zoonotic diseases

Zyme Communications
DNA Script’s SYNTAX® platform
Healthcare and Life Science 18 Mar 2026

DNA Script expands global access to on-demand DNA synthesis with distributor agreements in Latin America and East Asia

Enables researchers worldwide to access high-quality ssDNA oligonucleotides within hoursEstablishes direct distribution networks across Latin America, Japan and South Korea

Paris, France, 17 March 2026: DNA Script, a pioneer in DNA synt

Zyme Communications
Deyan Sultov, Co-founder and CTO (Left), and Dr Ryan Cawood, Co-founder and CEO (Right)
Healthcare and Life Science 16 Mar 2026

Lab Thread launches free version of Unified Lab Software Platform to accelerate academic research

Free-to-use software version available for academic and non-profit researchers worldwideIntuitive system provides robust data management tools to support scientific collaboration and engagement with funding bodies through streamlined adherence to FAIR data principles
Zyme Communications
VALANX Biotech
Healthcare and Life Science 12 Mar 2026

VALANX Biotech secures €3 million to advance LIV-1 ADC for metastatic triple-negative breast cancer

·        Foundation Fournier-Majoie and FUJIFILM Corporation join existing VC and angel investors including xista science ventures, tecnet equity and SOSV

Zyme Communications
Edward Bruce-White, Chief Executive Officer of Combat Medical
Healthcare and Life Science 12 Mar 2026

Combat Medical raises £2.6 million Series A to advance treatment of BCG unresponsive bladder cancer

Investment led by T&J Meyer Family Foundation, joined by Varia Ventures, NW Angel Fund and other non-institutional investorsFinancing advances Combat’s HIVEC® HEAT FDA registration trial to change standard of care in BCG unresponsive NMIBC
Zyme Communications
Kadans March 26
Healthcare and Life Science, Property and Utilities 12 Mar 2026

PINCH announces two major new contract wins as business growth continues into 2026

PINCH is proud to announce two significant new contract wins, marking an exciting start to the year and reinforcing the company’s continued growth across workplace catering, hospitality and events.

Zyme Communications
Dr. Debra Barker, Chief Medical Officer, Centauri Therapeutics and Daniel Hynes, VP of Development, Centauri Therapeutics
Healthcare and Life Science 10 Mar 2026

Centauri Therapeutics granted FDA QIDP status for CTX-187 treatment of Gram-negative bacterial infections

Lead clinical candidate CTX-187 is a novel antimicrobial immunotherapy developed to treat clinically-prevalent and multi-drug resistant Gram-negative bacterial infectionsQualified Infectious Disease Product designation awarded for the development of antibacterials and a
Zyme Communications
SpinPro® 6 R
Healthcare and Life Science 09 Mar 2026

Eppendorf introduces SpinPro® centrifuge series to streamline life science research

New Eppendorf SpinPro® 6 R centrifuge maximises workflow efficiency with flexible, ‘smart’ designCentrifuge showcased in ‘on demand’ video of virtual live launch

Hamburg, Germany, March 9, 2026 – Eppendorf, a leading internat

Zyme Communications
Cytotrait logo
Healthcare and Life Science 09 Mar 2026

Cytotrait secures £3M seed funding to address global food security and sustainable agriculture

Proprietary MOSS technology enables high-level, localised gene expression to overcome current challenges in crop engineeringInvestment round led by Northern Gritstone, with additional contributions from UK Innovation & Science Seed Fund and Northern Universities Ven
Zyme Communications
Pierre Arsène, Founder and CEO, Mursla Bio
Healthcare and Life Science 04 Mar 2026

Mursla Bio accelerates US commercial deployment of EvoLiver through ABHI Programme

Provides structured US market access for EvoLiver FDA-designated liver cancer surveillance test across health systems, payors and clinical stakeholders

Zyme Communications
OBN life sciences network
Healthcare and Life Science 03 Mar 2026

OBN Invites Life Science leaders to celebrate 20 years of BioTrinity

Featuring keynotes from: Steve Bates, Executive Chair at the Office for Life Sciences, Lawrence Tallon, CEO at the MHRA & Maria Koufali, Life Sciences Industry Director at the NIHR, click here
Zyme Communications
Rob Walton, CEO, SPT Labtech	Todd Christian, senior vice president of Services, Arrays, and Genomic Access, Illumina
Healthcare and Life Science 26 Feb 2026

SPT Labtech to collaborate with Illumina to develop automated platform supporting genomics in decentralized healthcare settings

SPT Labtech to develop an automated sample preparation platform for Illumina to further optimize the efficiency and benefits of genomic workflows in decentralized healthcare settingsBuilds on success of existing partnership including development of automated library pre
Zyme Communications
Rob Kirsner, M.D., PhD, Head of Medical Advisory Board at SolasCure, Chairman and Harvey Blank Professor of Dermatology at the University of Miami
Healthcare and Life Science 24 Feb 2026

SolasCure completes phase II clinical trial, demonstrating accelerated healing with Aurase Wound Gel

Aurase Wound Gel shows 22x faster debridement and 7x faster healing compared to standard of care in sloughy venous leg ulcers, supporting advancement to the next phase of developmentData confirms dual mechanism of action, including activation of tissue repair pathways i
Zyme Communications
Centauri Therapeutics
Healthcare and Life Science 24 Feb 2026

Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidate

Clinical candidate in ABX-01 programme, CTX-187, currently in development ahead of first in-human clinical trials to target Gram-negative bacterial infectionsInvestment from the world’s largest venture capital fund focused exclusively on antimicrobial therapeutics and d
Zyme Communications
Loughborough Sport’s performance laboratory
Healthcare and Life Science 23 Feb 2026

Loughborough University and Science in Sport (SiS) extend partnership in elite sport and performance nutrition

Loughborough and Blackburn, UK, 23 February 2026: Loughborough University and Science in Sport (SiS) announces a renewed three-year partnership, strengthening the organisations’ long-standing collaboration across elite sport and performance nutrition.

Zyme Communications
Dr Lara Zibners, Co-founder and Chairman (left), and Thang Vo-Ta, Co-founder and CEO (right), Calla Lily Clinical Care
Healthcare and Life Science 10 Feb 2026

Calla Lily Clinical Care and Merck announce strategic collaboration to advance intravaginal drug delivery platform

Enhancing patient treatment experience and care with a new self-administered solution for vaginal therapeuticsVersatile platform technology developed from a safe, award-winning, FDA-cleared medical deviceStrate
Zyme Communications
Carterra Vega™ High-Throughput Surface Plasmon Resonance (HT-SPR) instrument
Healthcare and Life Science 10 Feb 2026

Carterra launches industry’s first 48-channel HT-SPR platform for advanced label-free biomolecular screening and characterization

· Vega instrument combines ultra-high-throughput, data quality, and assay flexibility for both traditional and AI-based drug discovery

· Enables primary screening with high-resolution binding

Zyme Communications
SPT Labtech’s dragonfly® discovery system
Healthcare and Life Science 09 Feb 2026

SPT Labtech and BellBrook Labs introduce high-throughput screening platform for cancer research

·       Automated workflow to be highlighted at SLAS 2026, 7-11 February, Boston

Zyme Communications
Eppendorf
Healthcare and Life Science 09 Feb 2026

Eppendorf collaborates with Dubai Police to automate forensics laboratories

Access to automated instrumentation will enhance precision testing and improve analytical efficiency, streamlining criminal identification

Zyme Communications
Bio-Rad Laboratories, Inc
Healthcare and Life Science 09 Feb 2026

Bio-Rad receives AOAC international validation for EZ-Check Listeria spp. and EZ-Check Listeria monocytogenes Testing Kits

HERCULES, Calif. — February 6 2026 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announces it has received validation from AOAC International for its EZ-Check Listeria spp.

Zyme Communications
Synthace logo
Healthcare and Life Science 09 Feb 2026

Synthace collaborates with Charles River to offer the global pharma industry more robust, faster and cost-effective assays

Collaboration heralds new era of assay development in drug discovery 

Zyme Communications
Dr Mike Daniels,  Chief Commercial Officer, SynGenSys
Healthcare and Life Science 05 Feb 2026

SynGenSys introduces Liver.SET synthetic promoter library for liver-specific gene expression for in vivo gene therapies

Validated, tissue-specific library enables customisable and controllable liver-targeted gene expression with high specificity and minimal off-target activity in muscle tissue

Zyme Communications
logos
Healthcare and Life Science 27 Jan 2026

iXCells Biotechnologies and Rosebud Biosciences partner to advance organoid-based models for rare diseases

Expansion of iXCells’ iPSCore platform with integration of 3D human organoid expertise will enable evaluation of drug toxicity and tissue-specific responsesResponds to growing demand for scalable, patient-relevant human models to support translational decision-making in
Zyme Communications
Vortex Biotech
Healthcare and Life Science 27 Jan 2026

Vortex Biotech opens new state-of-the-art laboratory at Manchester Science Park

Expansion accelerates the development of its non-invasive cancer diagnostic solutions 

Pagination

  • First page «
  • Previous page ‹
  • …
  • Page 3
  • Page 4
  • Current page 5
  • Page 6
  • Page 7
  • …
  • Next page ›
  • Last page »
Receive our newsletter

Cambridge Network Limited is a company registered in England under company No. 3400152

The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

Email: [email protected], Tel: 01223 746801

© 2026 Cambridge Network. All Rights Reserved.

Website by KISS